Positive topline data announced from CARPO, Phase 2b trial of AuxoraTM in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of AuxoraTM in severe acute kidney injury (AKI), with data expected in 2025 LA JOLLA, Calif. , Aug. 12, 2024 /PRNewswire/ -- CalciMedica Inc.
("CalciMedica or the Company") (Nasdaq: CALC ), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended June 30, 2024 . "CalciMedica continues to progress steadily with the successful execution of multiple milestones across our pipeline. In the second quarter, we completed enrollment in our Phase 2b CARPO trial in patients with AP and subsequently announced positive topline data, which met our primary objective and further support Auxora's potential as an effective treatment for critically ill patients with acute inflammatory disease.
We look forward to sharing additional data from this trial later in the year and are also planning to meet with the FDA to discuss the design of a Phase 3 trial," said Rachel Leheny , Ph.D., Chief Executive Officer of CalciMedica.
"In addition, we are excited about KOURAGE, our Phase 2 trial in patients with severe AKI. We are enrolling patients and opening new sites and expect to share t.